I notice the filing content appears to be cut off partway through the balance sheet. However, there is sufficient substantive disclosure content (well over 150 words) to proceed with what is available.

Silence Therapeutics plc filed its quarterly report on Form 10-Q with the SEC on November 13, 2026, covering the fiscal quarter ended September 30, 2026, and disclosing a significant increase in cash and cash equivalents alongside a pending acquisition by Merck KGaA, Darmstadt, Germany.

Key Highlights

  • Cash position: Cash and cash equivalents stood at $247,659 thousand as of September 30, 2026, compared to $11,277 thousand as of December 31, 2025.
  • Short-term investments: Short-term investments were zero as of September 30, 2026, down from $73,837 thousand at December 31, 2025.
  • Total assets: Total assets were $281,498 thousand as of September 30, 2026, versus $131,442 thousand at December 31, 2025.
  • Shares outstanding: As of September 30, 2026, the registrant had 186,609,073 ordinary shares outstanding, nominal value £0.05 per share.
  • Pending acquisition: The filing identifies a proposed acquisition by Merck KGaA, Darmstadt, Germany, among its forward-looking disclosures, noting uncertainty around structure, timing, and ability to consummate the transaction.
  • Liquidity outlook: The company disclosed a belief that "existing cash, cash equivalents will be sufficient to fund our operating expenses and capital expenditure requirements at least until 2028."
  • Filer classification: Silence Therapeutics is classified as a non-accelerated filer and a smaller reporting company for this period.

Silence Therapeutics Reports Sharp Rise in Cash and Total Assets for September 30, 2026 Quarter

Silence Therapeutics plc (NASDAQ:SLN), a company incorporated in England and Wales and headquartered at 12 Hammersmith Grove, London, United Kingdom, filed its Form 10-Q for the quarterly period ended September 30, 2026. According to the filing, cash and cash equivalents increased sharply to $247,659 thousand at September 30, 2026, from $11,277 thousand at December 31, 2025. Over the same period, short-term investments fell from $73,837 thousand to zero, and total current assets rose from $118,658 thousand to $269,576 thousand.

The filing reports total assets of $281,498 thousand at September 30, 2026, up from $131,442 thousand at December 31, 2025. Other balance sheet items disclosed include goodwill of $10,254 thousand (compared to $10,621 thousand at year-end 2025), property, plant and equipment of $1,222 thousand, and an R&D benefit receivable of $9,973 thousand, down from $22,007 thousand at December 31, 2025. Total current liabilities were $(11,259) thousand at September 30, 2026, compared to $(13,613) thousand at December 31, 2025, with trade and other payables of $(11,172) thousand.

The filing discloses a proposed acquisition by Merck KGaA, Darmstadt, Germany, as a subject of forward-looking statements, with the company noting risks around the structure, timing, and ability to complete the transaction. The company's forward-looking statements are, according to the filing, subject to known and unknown risks and uncertainties, and "you should not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this Quarterly Report." The filing was submitted with Commission File Number 001-39487.

What Was Disclosed

Silence Therapeutics plc filed its Form 10-Q for the quarter ended September 30, 2026, reporting a large increase in cash and total assets versus year-end 2025, 186,609,073 ordinary shares outstanding, and a pending proposed acquisition by Merck KGaA, Darmstadt, Germany.